A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- NON RANDOMIZED · PARALLEL · TREATMENT · SINGLE
- Evidence population
- Human clinical study registration
- Participants
- 1000
- Population
- ALL · 50 Years
- Duration
- 2018-09-20 to 2029-12-31
- Intervention
- PDS Implant with Ranibizumab 100 mg/mL
- Comparator
- Not reported
- Outcomes measured
- Incidence and Severity of Ocular and Systemic (Non-Ocular) Adverse Events (AEs) — Baseline up to Week 240; Incidence, Severity, and Duration of Adverse Event of Special Interest (AESIs) — Baseline up to Week 240; Incidence, Severity, and Duration of PDS-Associated Ocular AESIs During the Postoperative Period (Up to 37 days of Init…; Incidence and Severity of Adverse Device Effects — Baseline up to Week 240; Incidence, Causality, Severity, And Duration Of Anticipated Serious Adverse Device Effects — Baseline up to Week 240; Sub-study 1: Rate of Vitreous Hemorrhage Secondary to Choroidal Bleeding That Does not Resolve by the Week 4 Visit Afte…; Sub-study 2: Number of Participants with Ocular and Systemic (Non-ocular) Adverse Events (AEs) and Severity of These AE…; Sub-study 2: Number of Participants with Adverse Events of Special Interests (AESIs) and Severity of AESIs — Baseline t…; Sub-study 2: Duration of AESIs — Baseline to Week 72; Sub-study 2: Number of participants with Ocular AESIs and Severity of Ocular AESIs During the Post-operative Period — U…; Sub-study 2: Number of participants with Ocular AESIs and Severity of Ocular AESIs During the Follow-up Period — > 37 d…; Sub-study 2: Duration of Ocular AESIs During the Post-operative Period — Up to Day 37 post re-implantation; Sub-study 2: Duration of Ocular AESIs During the Follow-up Period — > 37 days post re-implantation (up to approximately…; Sub-study 2: Number of Participants with Adverse Device Effects (ADEs) and Severity of ADEs — Baseline to Week 72; Sub-study 2: Number of Participants with Anticipated Serious ADEs and Severity of Anticipated Serious ADEs — Baseline t…; Sub-study 2: Duration of Anticipated Serious ADEs — Baseline to Week 72; Sub-study 2: Number of Device Deficiencies — Baseline to Week 72; Change in Best-Corrected Visual Acuity (BCVA) Score from Baseline Over Time, as Assessed using the ETDRS Visual Acuity…; Percentage of Participants who Lose <15, <10, or <5 Letters in BCVA Score from Baseline Over Time — Baseline up to Week…; Percentage of Participants with BCVA Score of 38 Letters (of 20/200 Approximate Snellen Equivalent) or Worse over Time…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.